Brief: NeuroBo Pharmaceuticals Completes Enrollment Of Part 1 Of Its Phase 2a Clinical Trial Evaluating DA-1241 For The Treatment Of MASH

MetaVia

01/04/2024 16:10

April 1 (Reuters) - Neurobo Pharmaceuticals Inc
 NRBO.O :
    * NEUROBO PHARMACEUTICALS INC: FULL DATA READOUT EXPECTED IN
SECOND HALF OF 2024
    * NEUROBO PHARMACEUTICALS COMPLETES ENROLLMENT OF PART 1 OF
ITS
PHASE 2A CLINICAL TRIAL EVALUATING DA-1241 FOR THE TREATMENT OF
MASH

Source text for Eikon:  ID:nPn6cPCjFa 
Further company coverage:  NRBO.O 

 ((Reuters.Briefs@thomsonreuters.com;))